Views

CrossRef citations to date

Altmetric

Research Article

Adverse Events and Clinical Outcomes in Patients Treated with PD-(L)1 Blockade for Advanced Non-Small-Cell Lung Cancer

Yan Zhang1 Bristol Myers Squibb,3401 Princeton Pike,Lawrence Township,NJ 08648,USAView further author information

Charlotte Doran2 ConcertAI,6555 Quince, Suite 400,Memphis,TN 38119,USAView further author information

Trong Kim Le1 Bristol Myers Squibb,3401 Princeton Pike,Lawrence Township,NJ 08648,USAView further author information

Brian Dreyfus1 Bristol Myers Squibb,3401 Princeton Pike,Lawrence Township,NJ 08648,USACorrespondence[email protected]

https://orcid.org/0000-0002-4241-9024 View further author information

Nina Kola1 Bristol Myers Squibb,3401 Princeton Pike,Lawrence Township,NJ 08648,USAView further author information

Brooke E Sylvester1 Bristol Myers Squibb,3401 Princeton Pike,Lawrence Township,NJ 08648,USAView further author information

Lincy Lal2 ConcertAI,6555 Quince, Suite 400,Memphis,TN 38119,USAView further author information

John R Penrod1 Bristol Myers Squibb,3401 Princeton Pike,Lawrence Township,NJ 08648,USAView further author information

Stephanie Meadows Shropshire1 Bristol Myers Squibb,3401 Princeton Pike,Lawrence Township,NJ 08648,USAView further author information

show all

Adverse Events and Clinical Outcomes in Patients Treated with PD-(L)1 Blockade for Advanced Non-Small-Cell Lung Cancer

Table 1. Patient characteristics at advanced/metastatic non-small-cell lung cancer diagnosis.

Table 2. Disease characteristics at advanced/metastatic non-small-cell lung cancer diagnosis.

Table 3. PD-(L)1 blockade therapy treatment patterns.

Table 4. Incidence of mild/moderate adverse events of interestTable Footnote^† during index PD-(L)1 blockade therapy by category and severity.

Table 5. Management actions performed for the first occurrence of mild/moderate adverse events of interestTable Footnote^† after initiation of index PD-(L)1 blockade therapy.

Table 6. Factors associated with overall survival from PD-(L)1 blockade treatment initiation.Table Footnote^†

Supplemental Figure 1. Study Schema

Supplemental Figure 2. Kaplan-Meier plots comparing patients with vs. without an AE by 3 monthsfor (A) duration of therapy, (B) time to next treatment, (C) progression-free survival; and (D) overall survival from the index date.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Adverse Events and Clinical Outcomes in Patients Treated with PD-(L)1 Blockade for Advanced Non-Small-Cell Lung Cancer

Figures & data

Table 1. Patient characteristics at advanced/metastatic non-small-cell lung cancer diagnosis.

Table 2. Disease characteristics at advanced/metastatic non-small-cell lung cancer diagnosis.

Table 3. PD-(L)1 blockade therapy treatment patterns.

Table 4. Incidence of mild/moderate adverse events of interestTable Footnote† during index PD-(L)1 blockade therapy by category and severity.

Table 5. Management actions performed for the first occurrence of mild/moderate adverse events of interestTable Footnote† after initiation of index PD-(L)1 blockade therapy.

Table 6. Factors associated with overall survival from PD-(L)1 blockade treatment initiation.Table Footnote†

Supplemental Figure 1. Study Schema

Supplemental Figure 2. Kaplan-Meier plots comparing patients with vs. without an AE by 3 monthsfor (A) duration of therapy, (B) time to next treatment, (C) progression-free survival; and (D) overall survival from the index date.

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 4. Incidence of mild/moderate adverse events of interestTable Footnote^† during index PD-(L)1 blockade therapy by category and severity.

Table 5. Management actions performed for the first occurrence of mild/moderate adverse events of interestTable Footnote^† after initiation of index PD-(L)1 blockade therapy.

Table 6. Factors associated with overall survival from PD-(L)1 blockade treatment initiation.Table Footnote^†